Aprea Therapeutics, Inc. (APRE) stock
Close on Nov 17, 2026Market cap $5.71MP/E –Yield –
Earnings
Aprea Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Aprea Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 15, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026before the open | – | – | -$0.09 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026before the open | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 16, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 12, 2025before the open | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025before the open | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025before the open | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 25, 2025before the open | $205.82K | +1362.3% | -$0.49 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $400.00K | – | -$0.64 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 12, 2024before the open | $600.00K | – | -$0.58 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 14, 2024before the open | $380.57K | – | -$0.67 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 26, 2024before the open | $14.08K | – | -$0.92 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023during market hours | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023before the open | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 15, 2023during market hours | – | – | -$1.34 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 30, 2023during market hours | – | – | -$0.92 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022during market hours | – | – | -$0.12 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 11, 2022during market hours | – | – | -$4.34 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022before the open | – | – | -$0.36 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 15, 2022during market hours | – | – | -$0.36 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 8, 2021during market hours | – | – | -$0.45 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 16, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Aprea Therapeutics guided for has been reported
Guidance history
Every forecast Aprea Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Mar 15, 2022 | cash burn | FY2022 | $25.00M – $30.00M | New |
| Nov 8, 2021 | cash burn | FY2021 | $30.00M – $35.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Aprea Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- Results
- Results
- Update
- Update
- Update
- Update
- Results
- Results
- News
- Update
See a number that looks wrong?